Lexicon Pharmaceuticals (NASDAQ:LXRX) released its earnings results on Thursday. The biopharmaceutical company reported $2.11 EPS for the quarter, beating analysts’ consensus estimates of $1.31 by $0.80, Fidelity Earnings reports. The business had revenue of $294.45 million for the quarter, compared to the consensus estimate of $12.00 million. During the same period in the prior year, the company posted ($0.26) EPS. The company’s quarterly revenue was up 4124.5% compared to the same quarter last year.
NASDAQ:LXRX traded down $0.36 during midday trading on Friday, hitting $3.52. The stock had a trading volume of 1,316,800 shares, compared to its average volume of 1,292,482. The company has a market capitalization of $419.77 million, a price-to-earnings ratio of -3.09 and a beta of 0.95. The stock has a 50-day moving average of $3.52 and a 200 day moving average of $4.21. Lexicon Pharmaceuticals has a one year low of $1.13 and a one year high of $9.15.
In other news, CEO Lonnel Coats bought 37,000 shares of Lexicon Pharmaceuticals stock in a transaction that occurred on Friday, August 16th. The stock was bought at an average price of $1.35 per share, for a total transaction of $49,950.00. Following the purchase, the chief executive officer now directly owns 87,695 shares of the company’s stock, valued at approximately $118,388.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Christopher J. Sobecki bought 25,000 shares of Lexicon Pharmaceuticals stock in a transaction that occurred on Monday, September 16th. The stock was purchased at an average price of $2.55 per share, with a total value of $63,750.00. Following the purchase, the director now directly owns 112,493 shares in the company, valued at $286,857.15. The disclosure for this purchase can be found here. Insiders purchased a total of 255,749 shares of company stock valued at $578,510 in the last 90 days. 6.40% of the stock is currently owned by company insiders.
Several brokerages recently issued reports on LXRX. Zacks Investment Research raised Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 price objective on the stock in a research note on Saturday. BidaskClub cut Lexicon Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 5th. Citigroup cut Lexicon Pharmaceuticals from a “buy” rating to a “neutral” rating and increased their price objective for the stock from $3.00 to $4.00 in a research note on Friday. Gabelli raised Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a research note on Wednesday, September 11th. Finally, ValuEngine raised Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $6.45.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.